Blood Clot Testing Device for Surgery Now Class II Approved
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a blood clot-checking device used during surgery as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for new, helpful devices to reach patients. Hospitals and device makers should get ready for these new rules, which aim to speed up access without extra costs.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device Classified as Class II
The FDA is officially classifying the coagulation system for measuring whole blood viscoelastic properties in perioperative patients as a Class II medical device with special controls. The agency says this classification provides a reasonable assurance of the device's safety and effectiveness.
Faster Patient Access Through Reduced Burdens
The FDA says this action will enhance patients' access to beneficial innovative devices in part by reducing regulatory burdens, which should make it easier for new devices to reach patients. The summary also notes the change aims to speed up access without extra costs.
Hospitals and Makers Should Prepare
The rule codifies special controls for this device type, and hospitals and device makers are advised to get ready for the new rules. The document indicates these changes are intended to reduce regulatory burdens while ensuring safety and effectiveness.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-08150 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens
The FDA is officially putting a special kind of medical device that spots tiny germs in patient samples into a safer, middle-level category called Class II. This change means the device will follow clear safety rules, helping patients get better access to cool new tech without extra red tape. If you make or use these devices, get ready for updated rules that keep things safe and effective, starting now!
Next: 2025-08169 — Safety Zone; Fireworks Displays Within the Fifth Coast Guard District; The Wharf, Washington, DC
The Coast Guard is setting up a safety zone around The Wharf in Washington, DC, during a fireworks show to keep everyone safe on the water. Boats won’t be allowed in the area unless they get special permission, and they must follow Coast Guard instructions. This temporary rule helps make sure the fireworks event goes off without a hitch, with no extra costs for boaters who follow the rules.